Winners across therapeutic areas are recognized by payers and physicians for their dedication for smoothing patient access.
Q3 2022 Winners
Oncology
AstraZeneca (Ovarian Cancer)
Bristol-Myers Squibb (Multiple Myeloma)
Janssen Pharmaceuticals (Prostate Cancer)
Biologics & Injectables
Janssen Pharmaceuticals (Crohn's Disease)
Janssen Pharmaceuticals (Ulcerative Colitis)
Jazz Pharmaceuticals (Narcolepsy)
ViiV Pharmaceuticals (HIV)
Q2 2022 Winners
Oncology
Novartis (Acute Lymphoblastic Leukemia)
Pfizer, Inc. (Acute Myeloid Leukemia)
Bristol-Myers Squibb (Chronic Myeloid Leukemia)
Bristol-Myers Squibb (Non-Hodgkin's Lymphoma)
Biologics & Injectables
Novo Nordisk (Diabetes)
Pfizer, Inc. (Atopic Dermatitis)
Janssen Pharmaceuticals (Psoriasis)
Amgen (Psoriatic Arthritis)
Sanofi (Severe Asthma)
Q1 2022 Winners
Oncology
Novartis (Breast Cancer)
Merck & Co. (Metastatic Melanoma)
Bristol-Myers Squibb (Non-Small Cell Lung Cancer)
Bristol-Myers Squibb (Bladder Cancer)
Biologics & Injectables
CSL Behring (Hereditary Angioedema)
Pfizer, Inc. (Growth Hormone Deficiency)
Janssen Pharmaceuticals (Growth Hormone Deficiency)
Novartis (Multiple Sclerosis)